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Abstract
Background: The purpose of this research is to develop and evaluate methods for conducting pragmatic cluster
randomized trials in a primary care electronic database. The proposal describes one application, in a less frequent
chronic condition of public health importance, secondary prevention of stroke. A related protocol in antibiotic
prescribing was reported previously.
Methods/Design: The study aims to implement a cluster randomized trial (CRT) using the electronic patient
records of the General Practice Research Database (GPRD) as a sampling frame and data source. The specific
objective of the trial is to evaluate the effectiveness of a computer-delivered intervention at enhancing the delivery
of stroke secondary prevention in primary care. GPRD family practices will be allocated to the intervention or usual
care. The intervention promotes the use of electronic prompts to support adherence with the recommendations of
the UK Intercollegiate Stroke Working Party and NICE guidelines for the secondary prevention of stroke in primary
care. Primary outcome measure will be the difference in systolic blood pressure between intervention and control
trial arms at 12-month follow-up. Secondary outcomes will be differences in serum cholesterol, prescribing of
antihypertensive drugs, statins, and antiplatelet therapy. The intervention will continue for 12 months. Information
on the utilization of the decision-support tools will also be analyzed.
Discussion: The CRT will investigate the effectiveness of using a computer-delivered intervention to reduce the risk
of stroke recurrence following a first stroke event. The study will provide methodological guidance on the
implementation of CRTs in electronic databases in primary care.
Trial registration: Current Controlled Trials ISRCTN35701810
Keywords: Clinical trials, Cluster analysis, Electronic health records, Feasibility studies, Stroke, Secondary prevention
Background
Stroke represents a leading cause of avoidable morbidity
and mortality in the UK with 130,000 stroke events per year
[1]. Patients who have had a first stroke have a considerably
elevated risk of a second stroke as well as increased risk of
myocardial infarction, lower limb ischemia, and other
vascular events [2,3]. The outcomes for those who have a
recurrent stroke are generally worse than after a first stroke,
with patients likely to experience increased disability and
higher healthcare costs over the longer term [4]. An im-
portant objective of preventive medical care is to reduce
the risk of recurrence of stroke and progression of vascular
disease.
Secondary prevention after a first stroke should include
lifestyle interventions to reduce overweight, increase exer-
cise, reduce alcohol intake and smoking, as well as atten-
tion to control of risk factors for cardiovascular disease
* Correspondence: alexandru.dregan@kcl.ac.uk
1King’s College London, Department of Primary Care and Public Health
Sciences, Division of Health and Social Care Research, Capital House, 42
Weston St, London SE1 3QD, UK
Full list of author information is available at the end of the article
TRIALS
© 2012 Dregan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Dregan et al. Trials 2012, 13:181
http://www.trialsjournal.com/content/13/1/181
including blood pressure (BP), serum cholesterol, and
antithrombotic treatment where appropriate [1,5,6].
National audits have revealed ‘major deficiencies’ in stroke
secondary prevention with 40% or fewer subjects achiev-
ing a target systolic blood pressure of <140 mm Hg at 6
months post stroke [7]. Stroke secondary prevention has
been specifically incentivized within the Quality and Out-
comes Framework (QOF) of the general practice contract
[8] with targets for treatment and control of blood pres-
sure (<150/90 mm Hg) and cholesterol (≤5 mmol/L), anti-
platelet or anticoagulant therapy for eligible patients, and
flu immunization [9]. However, these targets are flexible
with some 8% of patients being excluded as ‘exceptions’
and intermediate outcomes only requiring measurement
within the last 15 months to less stringent targets. While
the QOF strategy represents a ‘control’ intervention, a
more rigorous, evidence-based intervention strategy has
been recommended in the National Clinical Guidelines
for Stroke from the ICSWP [1], now in their third edition
[10]. These more stringent recommendations include: BP
should be controlled to <130/80 mm Hg in most patients;
all subjects with total cholesterol >4 mmol/L should be
treated with a statin unless there is evidence of
hemorrhagic stroke; and antiplatelet therapy should be
prescribed where appropriate.
The responsibility for delivering effective secondary
prevention, and managing long-term problems asso-
ciated with stroke, lies initially with the primary care
team. Considerable efforts have therefore been made to
enhance the quality of preventive medical care in general
practice and to increase the achievement of clinical tar-
gets for secondary prevention of stroke. The preferred
design to evaluate interventions aimed at changing
practitioner behavior and improve practice during con-
tact with patients is the cluster randomized trial (CRT)
[11-13]. A CRT design is appropriate when the unit of
intervention is a healthcare practitioner or a healthcare
organization such as a general practice. Well designed
CRTs may capitalize on the effects of within-group
learning, such as may occur when clinical decision sup-
port systems are deployed to primary care teams, while
minimizing cross-group contamination [14]. Van Staa et
al. [15] suggested that the utilization of large databases
of electronic health records may facilitate the implemen-
tation of pragmatic trials at low cost and with reduced
data collection burden for the clinician, health service,
or the patient. Use of electronic patient records facili-
tates the identification of all patients with a specific con-
dition registered at a particular practice [14], potentially
increasing the external validity of the study findings [15].
Therefore the proposed study will use a pragmatic CRT
to compare routine practice under QOF with a more
rigorous secondary prevention strategy as recommended
by the ICSWP.
This proposal will build on our experience of implement-
ing a CRT to enhance secondary prevention after stroke
utilizing the South London Stroke Register [16,17]. In a re-
cent cluster trial using stroke register data to inform stroke
care, Wolfe et al. [18] found no improvement in risk factor
management at 12-month follow-up. The trial was imple-
mented in an inner-city locality with a modest sample size
and collection of outcome data collection through inter-
action with participants could have primed the controls
about the aims of the trial potentially leading to positive
lifestyle changes or social desirability bias.
The present trial aims to compare routine practice
under QOF with a more rigorous secondary prevention
strategy as recommended by the ICSWP. The planned
trial will extend to practices throughout the UK. Individ-
ual participants will not be aware of the aims of the
intervention reducing the risk of contamination.
Methods/Design
Objective
The primary objective of the proposed study is to evaluate
whether a more intensive secondary prevention strategy,
delivered at the level of general practice and based on
evidence-based recommendations to control risk factors,
gives improved intermediate clinical outcomes and pro-
cesses of care following first stroke.
Study design
The effectiveness of a computer-delivered intervention
to promote secondary prevention of stroke will be tested
in a pragmatic cluster randomized trial with two trial
arms: usual care vs. computer-delivered recommenda-
tions for secondary prevention of stroke. The general
practice is chosen as the unit of allocation because the
intervention is implemented at the level of the general
practice. The duration of intervention is 12 months and
the first practices were allocated in April 2012.
Study setting and population
The study will take place in family practices in England,
Scotland, and Wales that contribute data to General
Practice Research Database (GPRD) which is part of the
Clinical Practice Research Datalink (CPRD). The age and
sex distribution of the GPRD registered population is
similar to the distribution of the UK population [19].
The study sample is represented by GPRD practices that
provide written consent to participate in the trial, in
areas that provide research governance approval of the
study. Study practices are recruited through a letter of
invitation sent from GPRD/MHRA. The intervention is
delivered through software known as DXS, and only
those GPRD practices that use DXS Point-of-Care will
be eligible to participate in the trial.
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Allocation
GPRD practices will be allocated to the two trial arms in
equal proportions. The allocation is by minimization
controlling for region in England (North (North-East
and North-West), Midlands (East and West Midlands),
South-East (South-East and East of England), South-
West, and London) and country in the UK (Scotland,
Wales, England) and list size (number of registered
patients). This list size was dichotomized for the
minimization using 7,500 as the cut-point. The alloca-
tion is performed at King’s College London using anon-
ymized practice identifiers supplied by the recruitment
team at GPRD/MHRA.
Intervention
The intervention comprises a series of electronic
prompts that promote adherence with evidence-based
recommendations for secondary prevention of stroke
and vascular disease following the National Guidelines
[5,6]. The development and implementation of the inter-
vention was informed by qualitative research for this
project [16,17] which was adapted to recent guidelines.
A key element of the intervention will be a series of elec-
tronic prompts that operationalize the ICSWP recom-
mendations. Control practices will continue with usual
care. The intervention will be implemented for 12
months at each practice. A detailed description of the
development and design of the electronic prompts is
provided in McDermott et al. [20]
Intervention implementation
Electronic prompts will be installed remotely at inter-
vention general practices. Electronic prompts will be
activated during eligible consultations. Consultations will
be eligible if the patient is aged ≥18 years and is included
on the practice stroke register. During consultations
with patients who have previously had a stroke, primary
care professionals will see the prompts which remind
them of evidence-based guidelines for secondary preven-
tion of stroke. The main focus is on targets for control
of blood pressure and cholesterol levels, appropriate pre-
scribing of aspirin and antiplatelet drugs, and enhanced
recording of stroke type (ischemic or hemorrhagic). The
prompts will also provide GPs with supporting informa-
tion, links to evidence that supports the recommenda-
tions, and options to print patient information. The
decision on whether to follow the treatment suggestions
included in the prompts will be at the discretion of the
GP. The GP will also be able to terminate display of the
prompt at any time. At the start of the study, a letter
containing instructions on the use of the prompts will
be sent to general practices in the intervention trial arm
for circulation to participating general practitioners. All
control practices will be sent a letter reminding them to
record any relevant consultation for eligible stroke
patients and to notify any adverse events. Three months
into the study, all intervention practices will receive an
email reminder containing instructions about the
prompts including aims and implementation.
Outcome evaluation
The evaluation of outcomes will be through analysis of
routinely-collected GPRD data during a defined study
period, while historical information will be used to assess
the baseline characteristics of the study patients. Infor-
mation routinely collected into GPRD for all registered
patients includes medical history, use of medicines, hos-
pitalizations and other resource use, smoking history, la-
boratory tests, letters from specialists or hospitals.
GPRD also now links patients in GPRD to the English
Hospital Episode Statistics, with detailed information on
date, duration, and reason for hospitalization. Availabil-
ity of data for all registered patients has potential to
minimize biases from subject selection/recruitment.
Electronic records will be included in analyses for all
patients on the practice’s stroke register. Participants
that were diagnosed with transient ischemic attacks only
will be excluded. The primary outcome measure is the
mean systolic BP after 12 months. Modeling will be used
to utilize BP values measured over time during the inter-
vention period. [21] Secondary outcomes will be mean
diastolic blood pressure; mean cholesterol concentration;
proportion of patients whose eligibility for anticoagu-
lants/antiplatelet drugs is defined; proportion of eligible
patients that receive anticoagulant/antiplatelet drugs;
prescription adherence with prescribed medicines; oc-
currence and hospitalization with vascular events includ-
ing TIA/stroke, myocardial infarction, new-onset angina,
and mortality. In light of recent changes in guidelines
for anti-platelet treatment, an additional outcome will be
the proportion of patients that received clopidogrel as
the first drug of choice. Recurrent stroke events will be
validated through anonymized records obtained from
practices. Linked HES data may be used to evaluate hos-
pital utilization. The method of Generalized Estimating
Equations will be implemented to allow for clustering by
practice, providing an analytical framework for both bin-
ary and continuous outcomes [22]. Last value carried
forward and multiple imputation will be used to deal
with missing values.
Process evaluation
The study will also evaluate the obstacles, barriers, and
facilitators to implementation of intervention research
within the GPRD. We will conduct an intervention
evaluation study towards the end of the trial including
both staff at GPRD and study practices via an electronic
questionnaire to ensure the anonymity of practices is
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maintained. General practices in the ‘control’ arm of the
study will only be asked to complete two questions on
‘views and opinions’. In addition, practices who agreed
to a telephone interview at the time of consent for the
trial will be contacted for a telephone interview at the
end of the study to discuss GPs’ opinions and feedback
of experiences of taking part in the trial.
Sample size calculation
The sample size calculation is based on a comparison be-
tween the trial intervention and usual care, represented by
the targets included in the quality and outcomes frame-
work (QOF) for stroke. Thus the QOF recommends a
blood pressure target for stroke patients of 150/90 mm
Hg while the trial prompts, following the ICSWP guide-
lines, recommend a target of 130/80 mm Hg. The age-
standardized incidence of first stroke is between 1.74 and
2.16 per 1,000 in England [2,23]. In 375 GPRD practices
in 2006, there were approximately 14.5 first strokes per
practice per year (ISAC protocol 07–027). We propose to
include for analysis all subjects whose first stroke was in
the 2 years preceding the intervention start date, giving
about 29 subjects per practice eligible for analysis. If the
standard deviation of systolic BP in these subjects is 19
mm Hg [24,25] with an ICC by general practice of 0.032
[26], with a two-sided alpha=0.05, power=0.8, then to de-
tect a 2.75 mm Hg difference in systolic blood pressure,
about 99 practices will be required with 50 receiving the
active intervention. This represents an effect size of 0.14.
In reality, the number of patients per practice will be vari-
able and the coefficient of variation of practice size may
be approximately 0.65 [27]. This means that the effective
number of practices is approximately 83 and the detect-
able difference in systolic BP will be approximately 3mm
Hg. Analysis of GPRD data for stroke shows a high pro-
portion of stroke patients had blood pressure recordings
in 2006 with a mean of three blood pressure records per
patient.
Ethics
The study protocol and associated documents have
received approval/favorable opinion from the National
Research Ethics Service Committee London - South
West (REC number: 08/H0801/113) and from the R&D
from participating Primary Care Trusts (PCTs) or Health
Boards (HB). Protocol amendments have received REC
approval and approval/favorable opinion from participat-
ing PCTs and HBs. A senior partner at each participat-
ing general practice will be asked to give written
informed consent to take part in the study [27].
Discussion
This study, together with a previously reported trial in anti-
biotic prescribing [28], will provide evidence concerning
the feasibility of implementing CRTs using electronic data-
bases and its effectiveness in preventing stroke recurrence
and associated vascular events. The methodology developed
through this project will have wide potential for application
in future research with primary care electronic databases. A
key output from the research will therefore be a set of
methodological guidelines that will identify and analyze the
component tasks of implementing a cluster trial through
electronic patient records.
Cluster trials are susceptible to bias and the imple-
mentation of a cluster trial within an electronic database
offers the opportunity to evaluate such biases. For ex-
ample, in practices allocated to the intervention the
intervention may be associated with increased recruit-
ment rate [29]. Also, the behavior of professionals at
control practices may be modified through their partici-
pation in the study even though they are not exposed to
the intervention [28].
These potential biases may be evaluated by comparing
number of stroke patients at intervention practices prior
to and after the intervention and also comparing
changes in secondary prevention activity between non-
participating and participating practices.
Trial status
Practice recruitment stage.
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